Former Merck CEO Roy Vagelos says NIH shouldn't be playing the drug development game, reports Katherine Hobson on the Wall Street Journal's Health blog. In December, NIH proposed the creation of the National Center for Advancing Translational Sciences, and has been fending off criticism from the research community ever since. NIH says that it hopes the new center will drive promising drug discovery and could eventually license promising compounds to pharma and biotech companies, Hobson says. But at a panel at the annual meeting of the Pharmaceutical Research and Manufacturers of America, Vagelos told the audience that translational research isn't the proper function of NIH and its money, calling it "the pathway to destruction," Hobson says. Instead, Vagelos said, the agency should stick to funding basic research.
'Stick' With What You Know
Apr 18, 2011